Activiomics Inks Deal with UCB; Aims to Raise $1M in Venture Funding Early Next Year
December 10, 2010
Activiomics Inks Deal with UCB; Aims to Raise $1M in Venture Funding Early Next Year
The agreement calls for the company to apply its mass spec-based phosphoproteomics platform to the study of cell signaling pathways targeted by UCB's therapeutic antibodies and to identify potential protein biomarkers linked to the drugs.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Activiomics Raises $800K in Funding
March 18, 2011 / ProteoMonitor - Duke Team Identifies Phosphoprotein Signatures That Could Predict Breast Cancer Risk
November 12, 2010 / ProteoMonitor - NCI's Plan for Clinical Proteomics Initiative Spurs Questions about Sourcing of Patient Samples
August 27, 2010 / ProteoMonitor - GMU's Petricoin Building Database That Details Activation in Cancer Protein Pathways
August 13, 2010 / ProteoMonitor - Hutch, Broad Teams Publish Comprehensive Methods for MS-Based Biomarker Discovery and Verification
July 29, 2011 / ProteoMonitor